Head-To-Head Contrast: Pharma Bio Serv (PBSV) & The Competition
Pharma Bio Serv (OTCMKTS: PBSV) is one of 26 public companies in the “Management consulting services” industry, but how does it contrast to its peers? We will compare Pharma Bio Serv to related companies based on the strength of its risk, dividends, earnings, valuation, profitability, analyst recommendations and institutional ownership.
This is a summary of recent recommendations for Pharma Bio Serv and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pharma Bio Serv||0||0||0||0||N/A|
|Pharma Bio Serv Competitors||122||399||574||29||2.45|
This table compares Pharma Bio Serv and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pharma Bio Serv||-14.93%||0.49%||0.41%|
|Pharma Bio Serv Competitors||-18.21%||-37.44%||-2.73%|
Risk and Volatility
Pharma Bio Serv has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Pharma Bio Serv’s peers have a beta of 0.62, suggesting that their average share price is 38% less volatile than the S&P 500.
Pharma Bio Serv pays an annual dividend of $0.08 per share and has a dividend yield of 7.3%. Pharma Bio Serv pays out -133.3% of its earnings in the form of a dividend. As a group, “Management consulting services” companies pay a dividend yield of 1.4% and pay out 32.7% of their earnings in the form of a dividend. Pharma Bio Serv is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.
Institutional and Insider Ownership
65.3% of shares of all “Management consulting services” companies are owned by institutional investors. 51.6% of Pharma Bio Serv shares are owned by company insiders. Comparatively, 13.3% of shares of all “Management consulting services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Pharma Bio Serv and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pharma Bio Serv||$15.58 million||-$1.41 million||-18.33|
|Pharma Bio Serv Competitors||$993.84 million||$66.10 million||15.17|
Pharma Bio Serv’s peers have higher revenue and earnings than Pharma Bio Serv. Pharma Bio Serv is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About Pharma Bio Serv
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm with a laboratory testing facility in Puerto Rico, the United States, Europe, and Brazil markets. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company's technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. It also offers microbiological and chemical testing services through its lab; and technical trainings/seminars. The company markets its services through industry trade shows, professional conventions, industry publications, and seminars. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Receive News & Ratings for Pharma Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.